Back to Search
Start Over
Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials
- Source :
- Cancer Medicine, Vol 9, Iss 11, Pp 3656-3667 (2020), Cancer Medicine
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- The time course of the response to each drug is important to avoid inappropriate termination of treatment by misjudging tumor progression; however, little is known about soft tissue sarcoma (STS) regarding this matter. This study aimed to perform a time‐lapse analysis of tumor response in patients with STS treated with trabectedin from 2 phase II clinical trials. We examined 66 patients with translocation‐related sarcoma registered in 2 Japanese phase II clinical trials. All patients previously received standard therapy before the administration of trabectedin at 1.2 mg/m2 every 3 weeks. Imaging evaluation was performed according to the study protocol. The sum of the maximum diameters of the target lesions was calculated and analyzed over time. Among the 66 patients, 9 (13.6%) showed partial response (PR) to trabectedin. Histological diagnoses of these 9 responders comprised 6 myxoid liposarcoma, 2 synovial sarcoma, and a mesenchymal chondrosarcoma. The median period from treatment initiation to the first PR was 123 (range, 34‐328) days. The pattern of tumor response to trabectedin showed an increasing tendency in size in the initial stage, usually followed by a size decrease with repeated administration. STS response to trabectedin was characterized as delayed and potentially persistent. Clinicians treating STS with trabectedin should know the features of the response pattern to avoid interrupting the treatment before maximal efficacy is achieved.<br />Among 66 patients with translocation‐related sarcoma, 9 showed partial response to trabectedin, and 5 of the 9 responders (56%) fulfilled the criteria for partial response later than 100 days from treatment initiation. Tumor response to trabectedin was characterized as delayed and stabilized by the detailed time‐lapse analysis of tumor size.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Phases of clinical research
chemotherapy
Time-Lapse Imaging
lcsh:RC254-282
Young Adult
03 medical and health sciences
Clinical Trials, Phase II as Topic
0302 clinical medicine
Internal medicine
medicine
Humans
Multicenter Studies as Topic
Radiology, Nuclear Medicine and imaging
Antineoplastic Agents, Alkylating
Trabectedin
Original Research
Aged
Aged, 80 and over
Myxoid liposarcoma
business.industry
Soft tissue sarcoma
Clinical Cancer Research
Sarcoma
clinical trial
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Mesenchymal chondrosarcoma
Synovial sarcoma
030104 developmental biology
Tumor progression
soft tissue sarcoma
030220 oncology & carcinogenesis
Female
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....b9ef09b08dfa4520a31f03df17b70e98